We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Molecular Diagnostic Tool Evaluated for Malaria

By LabMedica International staff writers
Posted on 03 Mar 2014
Print article
Image: The Stratagene Mx3000P real-time PCR system (Photo courtesy of Agilent).
Image: The Stratagene Mx3000P real-time PCR system (Photo courtesy of Agilent).
The diagnostic potential of a recently developed photo-induced electron transfer fluorogenic primer (PET) real-time polymerase chain reaction (PCR) called PET-PCR has been investigated for diagnosing malaria.

Accurate diagnosis of malaria infections remains challenging, especially in the identification of submicroscopic infections and molecular diagnostic tools that are inexpensive, sensitive enough to detect low-level infections are needed in laboratory settings of resource-limited countries.

Scientists at the University of Georgia (Athens, GA, USA) working with colleagues in East Africa, obtained 303 blood samples from a survey conducted in the Iringa region of Tanzania. Both thick and thin smears were prepared for each sample and DNA was extracted and isolated as well. All samples were screened using the multiplex PET-PCR assay designed to detect Plasmodium genus and P. falciparum initially in laboratory in Tanzania and then repeated at a reference laboratory, the Centers of Disease Control and Prevention (CDC; Atlanta, GA, USA).

A subset of the samples were tested in a blinded fashion to find the sensitivity and specificity of the PET-PCR compared to the nested 18S ribosomal ribonucleic acid (rRNA) PCR. The Stratagene Mx3000P real-time PCR system (Agilent; Santa Clara, CA, USA) was used to test all samples in both the Ifakara Health Institute (Dar es Salaam; Tanzania) and at the CDC.

Twenty-seven samples out of the 303 tested were found to be positive for both P. falciparum and Plasmodium spp. by PET-PCR when performed in both laboratories. Microscopy detected 11 positive samples (3.63%) among the 303 samples tested, and these microscopy positive samples were confirmed to be positive by PET-PCR. In addition, 16 microscopy-negative samples were found to be positive for both P. falciparum and Plasmodium spp. by PET-PCR. The data showed 100% sensitivity and specificity for the PET-PCR assay and 40% sensitivity and 100% specificity for microscopy.

As the goal moves towards malaria elimination, newer tools that are able to detect all malaria cases, including low-density infections not detectable by microscopy, or rapid diagnostic tests (RDTs), and that are applicable to large-scale screening, are required. The authors concluded that PET-PCR as a new molecular diagnostic tool has similar performance characteristics as commonly used PCR methods, but is less expensive, easier to use, and suitable for large scale-surveillance studies in developing country settings. The study was published on January 27, 2014, in the Malaria Journal.

Related Links:

University of Georgia
Agilent
Ifakara Health Institute



Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centrifuge
Hematocrit Centrifuge 7511M4
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.